𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of lymphoplasmapheresis on clinical indices and t cell subsets in rheumatoid arthritis a double-blind controlled study

✍ Scribed by Wilfried Verdickt; Prof.; Dr. Jan Dequeker; Jan L. Ceuppens; Erik Stevens; Koo Gautama; Carl Vermylen


Publisher
John Wiley and Sons
Year
1983
Tongue
English
Weight
671 KB
Volume
26
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis


The effects of lymphoplasmapheresis on immunologic indices, including T cell subsets, and on clinical parameters of rheumatoid arthritis were evaluated in a controlled double-blind trial. Twenty patients were randomized to receive either 6 lymphoplasmapheresis sessions or a seemingly identical control procedure over a 3-week period. Lymphoplasmapheresis produced significant reduction in serum levels of total lymphocytes, erythrocyte sedimentation rate, C-reactive protein, and IgG. These serologic measures returned to baseline 5 weeks after lymphoplasmapheresis. No change in the imbalance of T cell subsets (increased helper/suppressor ratio) was observed. No changes in the serologic measures, except IgA, were observed in the control group. An improvement in some of the clinical parameters was observed in both the lymphoplasmapheresis and control groups. A rebound above baseline values for several parameters was observed in both the lymphoplasmapheresis and the sham apheresis groups.


πŸ“œ SIMILAR VOLUMES


A double-blind, placebo-controlled study
✍ Nancy J. Olsen; Raye H. Brooks; John J. Cush; Peter E. Lipsky; E. William St. Cl πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 654 KB

Objective. To evaluate the efficacy of an antLCD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double-blind, multiple-dose, placebo-controlled study of CDS-IC. Results. Treatment with CD

A randomized, double-blind, placebo-cont
✍ Peter A. Van Der Lubbe; Ben A. C. Dijkmans; Hendrik M. Markusse; Ulla NΓ€ssander; πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 920 KB

To assess the efficacy of the CD4 monoclonal antibody (MAb) cM-T412 in the treatment of early rheumatoid arthritis (RA). Methods. Sixty patients were enrolled in a 6-week randomized, double-blind, placebo-controlled study investigating multiple dose regimens of cM-T412. Thirty patients subsequently